In a post on To the Point, former congressman Henry Waxman and colleagues Bill Corr and Kristi Martin explain how the Bipartisan Budget Act of 2018 ensures that manufacturers of brand-name drugs cannot take advantage of inappropriately low Medicaid rebates. The deal also includes two other provisions that should save Medicare beneficiaries and the federal government money.
Bipartisan Deal Takes Important Step to Control Medicaid Drug Prices, But More Is Needed
![436x125 Line Extension in Medicaid Drug Pricing](/sites/default/files/styles/hero_image_desktop/public/images/___media_upload_medications_line_extension_in_medicaid_drug_pricing.jpg?itok=w4ykRVhH)